This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Red Cross moves to dismiss US antitrust claims

( April 17, 2023, 20:21 GMT | Official Statement) -- MLex Summary: While Verax Biomedical may not agree with the decision, the American National Red Cross’ adoption of pathogen reduction technology didn't violate any antitrust laws, the Red Cross told a US federal judge in a motion to dismiss Verax’s antitrust claims. “Verax has a commercial challenge — it is flailing in its efforts to sell its PGDprime rapid test to hospital customers today. But rather than innovating or proving the value proposition of PGDprime to its hospital customers, Verax brings this case against the Red Cross, which is not Verax’s competitor or supplier,” it argued.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections